Integrated genomic sequencing and mutational profiling provides insight into the molecular origin of phyllodes tumors and indicates potential druggable targets in malignant disease.
Introduction
Phyllodes tumors of the breast are relatively rare fibroepithelial tumors that account for approximately 1% of all breast neoplasms. Like benign breast fibroadenomas they are characterized by proliferation of both stromal and epithelial components, but in contrast they have considerable malignant potential. Phyllodes tumors are classified as benign (~65%), borderline (~25%) and malignant (~10%) based on histological features including cellular atypia, mitotic activity, stromal overgrowth, stromal cellularity and tumor margins(1). However, this histopathological classification often fails to predict which phyllodes tumors will recur or metastasize after treatment and does not accurately inform on treatment options. While local recurrence after resection is most prevalent in histologically malignant cases (approximately 30%, depending on width of excised margins), borderline and benign tumors can also recur locally in about 15% and 10% of cases, respectively, demonstrating the limitations of current prognostic approaches (2) . Likewise, while ~10% of all phyllodes tumors progress to distant metastases, only ~20% of histologically malignant cases do so (3, 4) , leaving a substantial number of borderline and even histologically benign cases that have metastatic potential.
Conversely, although most histologically benign cases will behave as such, there are a proportion of phyllodes tumors classified as malignant and borderline that will behave in a benign manner.
Current treatment guidelines for phyllodes tumors require wide surgical resection margins, but efficacious treatment options for the 10% of all phyllodes tumors that progress to metastatic disease are lacking and survival rates are dismal (3) . gains of chromosome 1q and losses in 13q, 6q, 9p, however their prognostic utility is unclear (5) (6) (7) (8) (9) . Several genes have been implicated in phyllodes tumor development by virtue of being localized to areas of CNA, including EGFR, which was recently shown by fluorescence in situ hybridization (FISH) to be amplified in 2-16% of cases (10, 11) . In addition, gene expression and IHC studies have implicated various signaling pathways, including IGF and Wnt/β Catenin as being activated in phyllodes tumors(1). To more comprehensively assess somatic molecular alterations in phyllodes tumors and identify potential opportunities for personalized medicine, we performed next generation sequencing (NGS) of 15 formalin fixed paraffin embedded (FFPE) phyllodes tumors representing the histologic grade spectrum.
Materials and Methods

Case Selection
We identified a cohort of 15 archived, routine clinical FFPE phyllodes tumor specimens from the University of Michigan Department of Pathology Tissue Archive. Clinicopathological information for each case was obtained from the clinical archive. Hematoxylin and eosin (H&E) stained slides for all cases were reviewed by a board-certified Anatomic Pathologist (S.A.T.) to ensure sufficient tumor content and confirm histologic grade.
Targeted Next Generation Sequencing
Targeted next generation sequencing of tumor tissue was performed with IRB approval.
For each specimen, 4-10 x 10um FFPE sections were cut from a single representative block per case, using macrodissection with a scalpel as needed to enrich for at least 50% tumor content (as defined by areas of stromal overgrowth). DNA was isolated using the Qiagen Allprep FFPE DNA/RNA kit (Qiagen, Valencia, CA), according to the manufacturer's instructions except for adding a 2 minute room temperature incubation and extending centrifugation time to 5 minutes during the xylene deparaffinization (step 1) and ethanol washing of xylene (step 2). DNA was quantified using the Qubit 2.0 fluorometer (Life Technologies, Foster City, CA). Data analysis was performed essentially as described (12) in Torrent Suite 4.0.2, with alignment by TMAP using default parameters, and variant calling using the Torrent Variant Caller plugin (version 4.0-r76860) using default low-stringency somatic variant settings.
Variants were annotated using Annovar (13) . Called variants were filtered to remove synonymous 
Copy number analysis
To identify copy number alterations, normalized, GC-content corrected read counts per amplicon for each sample were divided by those from a pool of normal male genomic DNA samples (FFPE and frozen tissue, individual and pooled samples), yielding a copy number ratio for each amplicon. Gene-level copy number estimates were determined by taking the coverage- Genes with a log 2 copy number estimate of <-1 or >0.6 were considered to have high level loss or gain, respectively.
Sanger sequencing to validate called somatic variants
Bi-directional Sanger sequencing was performed over the observed MED12 mutation hotspot (G44) on all tumor samples. Ten nanograms of genomic DNA was used as template in PCR amplifications with Invitrogen Platinum PCR Supermix Hi-Fi (Life Technologies, Foster City, CA) with the suggested initial denaturation and cycling conditions. Primer sequences were as previously reported (14, 15) and IGF1R were determined by the ∆∆CT method using the average C t of DNMT3A, FBXW7
and MYO18A as the reference (copy number neutral by NGS in all PH samples) and PH 22 (copy number neutral by NGS) as the calibrator sample.
Statistics
Comparisons of the number of mutations or copy number alterations per sample by tumor grade were performed using the Kruskal-Wallis test with post-hoc pairwise comparison of subgroups using MedCalc 13.1.2.0. Comparison of the frequency of MED12 mutations by tumor grade was performed by the Fisher's exact test using R 3.1.0.
Results
We performed targeted NGS on a cohort of 15 FFPE phyllodes tumors comprised of 5 cases each of benign, borderline and malignant histological grade; representative photomicrographs and clinical characteristics of all patients are presented in Figure 1A . We isolated an average of 0.65ug DNA per case from 4-10 x 10um sections using macrodissection to enrich tumor content as needed. NGS was performed using a multiplexed PCR based custom Ion NGS of multiplexed templates on the Ion Torrent PGM generated an average of 1,011,571 mapped reads yielding 409x targeted base coverage across the 15 samples (Table S1 ).
We identified a total of 26 high-confidence, likely somatic non-synonymous or splice site By NGS, we found that MED12, which encodes subunit 12 of the Mediator complex (the multi-protein assembly that serves as a general co-activator of transcription by RNA polymerase II) was mutated in 10/15 samples (67%; one sample with biallelic mutations) by automated variant calling and visual read inspection in IGV (as some called variants were filtered due to skewed read support). All mutations were localized to the exon 2 hotspot region near residue G44 (Figure 2A & Table S2&3 ), which has recently been reported to be recurrently mutated at 
high frequency in uterine leiomyomas (14) (15) (16) and benign breast fibroadenomas (17) , and more rarely in uterine leiomyosarcomas (15, 16, 18, 19) . Five of 11 total MED12 mutations were point mutations at G44 (3 p.G44S, 1 p.G44C, 1 p.G44R) while 3 mutations were frame-preserving deletions adjacent to or including G44 (p.38_43, p.41_49, p.42_51). Two mutations were intronic point mutations just upstream of exon 2, at a previously reported splice acceptor site causing retention of an additional 6 bases in the transcript (c.IVS-8 p.E33_D34insPQ) (14, 17) . high level EGFR (copy number ratio > 6) and IGF1R amplifications, while PH-16 also showed a high-level IGF1R amplification (copy number ratio > 32, Figure 3B ). TERT amplifications were also observed in three malignant tumors, while PH-05 harbored a focal high level CDKN2A (p16INK4A) loss. We confirmed EGFR, IGF1R and CDKN2A CNAs by quantitative real-time PCR (qPCR) as shown in Figure 3C .
Discussion
We performed targeted NGS of 15 FFPE phyllodes tumors representing all three histological grades to identify somatic alterations associated with tumor development and potential targetable alterations. Mutations in MED12 were present in 10 of 15 cases (67%) and affected the known exon 2 G44 residue hotspot through multiple mechanisms. No significant difference in MED12 mutation frequency was observed across histologic grades, although our cohort size is limited. Our IRB approved protocol does not allow NGS of matched normal tissue, however the observed MED12 variant allele frequencies are consistent with somatic events as seen in other tumors. Similar MED12 somatic mutations are frequent (50-70%) in benign uterine leiomyomas(14-16) but less common in malignant uterine leiomyosarcomas (7-30%) (15, 16, 18, 19) . Recently, Lim et al identified similar MED12 mutations in 59% of benign breast fibroadenomas through exome sequencing (17) . Given the morphological similarity of breast fibroadenomas and benign phyllodes tumors, frequent MED12 mutations in both entities support a closely related molecular origin. Additionally, although our findings will need to be replicated in larger cohorts, the similar frequency of MED12 mutations across the histologic spectrum of phyllodes tumors (in addition to benign fibroadenomas) suggests that MED12 mutations in the breast are early events which may be unrelated to malignant behavior, in contrast to uterine 13% of cases respectively (1/5 and 2/5 malignant cases). EGFR has been shown to be highly amplified in phyllodes tumors by FISH in up to 16% of cases (10, 11) , consistent with our findings. Dysregulation of the IGF pathway has been implicated in phyllodes tumors by IHC(1), however IGF1R amplification has not been reported.
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